Insulet delivered a strong Q1'26 with total revenue up 30% constant currency, raised its full-year revenue guidance for total and international segments, and reaffirmed its EPS and margin expansion targets. The company navigated US seasonality headwinds and a voluntary medical device correction, emphasizing strength in international markets and continued progress in Type 2 diabetes. Q1'26 revenue grew 30% CC, exceeding the high end of guidance, driven by strong US (28%) and international (45%) performance.
Buzzberg readQ1 revenue growth 30%, full-year guidance raisedInsulet delivered a strong Q1'26 with total revenue up 30% constant currency, raised its full-year revenue guidance for total and international segments, and reaffirmed its EPS and margin expansion targets. The company navigated US seasonality headwinds and a voluntary medical device correction, emphasizing strength in international markets and continued progress in Type 2 diabetes. Q1'26 revenue grew 30% CC, exceeding the high end of guidance, driven by strong US (28%) and international (45%) performance.Read full analysisCollapse analysis
Insulet delivered a strong Q1'26 with total revenue up 30% constant currency, raised its full-year revenue guidance for total and international segments, and reaffirmed its EPS and margin expansion targets. The company navigated US seasonality headwinds and a voluntary medical device correction, emphasizing strength in international markets and continued progress in Type 2 diabetes. Q1'26 revenue grew 30% CC, exceeding the high end of guidance, driven by strong US (28%) and international (45%) performance.
Raised FY'26 total company revenue growth to 21-23% and international Omnipod growth to 26-28%, maintaining US Omnipod at 20-22%.
US new customer starts grew YoY despite 'greater than normal seasonality' from deductible resets, with improving momentum into April.
The integration with Abbott's Libre 3 Plus sensor is set to unlock an additional 450,000 users in the US.
INTERNATIONAL_OMNIPOD rev growth45%
reported
Revenue$0.7617B
-3% QoQ
TOTAL_COMPANY revenue$762M
reported
US_OMNIPOD rev growth28%
reported
What changed this quarter
01
Guidance
Q1 revenue growth 30%, full-year guidance raised
Guidance tone
02
Product Launch
Libre 3 Plus integration unlocks 450,000 patient TAM
Q1'26 revenue grew 30% CC, exceeding the high end of guidance, driven by strong US (28%) and international (45%) performance.
03
Innovation
First participant enrolled in Evolve pivotal study
Raised FY'26 total company revenue growth to 21-23% and international Omnipod growth to 26-28%, maintaining US Omnipod at 20-22%.
04
Demand
US Type 2 new starts grew despite seasonality
Management expressed strong confidence in growth and strategic execution, citing record results, raised guidance, and multiple catalysts.
Demand & capex
Demand
Bookings & conversion
US Type 2 new starts grew despite seasonality. Management expressed strong confidence in growth and strategic execution, citing record results, raised guidance, and multiple catalysts.
Capex
Investment and capacity
Management is increasing investments to support innovation and global manufacturing expansion, with capital expenditures ramping in 2026 and a new Costa Rica facility expected to go live in 2029, and they expect free cash flow to be approximately flat due to this capex ramp.
Tone · Confident
Management expressed strong confidence in growth and strategic execution, citing record results, raised guidance, and multiple catalysts.
Supply-chain alpha
A1
Despite facing a 'slower start' due to US seasonality from deductible resets, management sees improving month-on-month trends and remains confident in the US outlook, suggesting Q1 weakness was temporary rather than structural.
“Improving month-on-month trends over the course of the quarter and into April suggests this was a temporary headwind, and we remain confident in our U.S. outlook for the full year.”
The Type 2 segment is a critical growth driver, with MS management indicating that the total company retention rate is expected to decrease modestly as Type 2 mix grows, necessitating targeted retention investments.
“We do expect retention rates to decrease modestly as our type 2 customer base continues to grow, which is why we're investing in programs focused on improving onboarding, engagement, and long-term retention.”
Thank you. Good morning. I appreciate your taking the questions here. Maybe I'll just start with a strategic one and then go on to the financials. Ashley, I think you've been in the role now just about a year. Maybe you could help frame the past year, some of your observations here. What's gone in line with your expectations? What's gone better? Where are the areas where you're focused? And how are you kind of framing insulin now that you've been in the role 12 months?
Yeah. Thank you, David, for joining. I was just last week. I marked my one year and I would say that I'm absolutely more confident now than, than insulin's potential than a year ago. You know us really as this high growth med tech innovator, doubling revenue over the past couple of years. So I would say first and foremost, I'm preserving what makes us so special. It's this culture is remarkable and patient focus, entrepreneurial spirit, and really strong competitive notes and really just focusing around how we enhance our capabilities to really double the business once again. So maybe it's just helpful to share some of the areas that we've been getting after as a team to unlock more value. I would first start with innovation, and this is about doing things in parallel and at pace to continue our role as the tech leader. So let me give you examples. It's really about being first in line to integrate day one with sensors, like we're doing with the Dexcom 15 day. And we will do with Abbott's upcoming dual analyte sensor. Algorithms. You know, David, we were slow out of the gate continuously to improve our algorithms. We've addressed that now. And we have three algorithm improvements over the next three years. Second is really about international and driving profitable growth globally. So I'm a big believer in going deeper in core markets that matter most versus going broader at this stage. And the UK is a great example of this. We're several years in the OP5 launch. This quarter, we posted record NCS. The third is about our commercial engine and being famous, not just as a tech leader, but as a commercial engine. And so we have our second Salesforce expansion we've done in the past 12 months. It's happening this quarter. And as I've been consistently saying, it's really upskilling our force to sell clinically. The fourth is really about strengthening our unbelievable foundation on operations as we scale globally. Costa Rica is a really good example of this. We just put in the foundation this quarter. We'll be ready to have a watertight building by year end and go live in 2029. And obviously it's all about people. You know, I came here and there was a remarkably talented team and I'm just supplementing that team with some new leaders that have run bigger things and know how to scale. So collectively, you know, we can get after doubling the business again. So …
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.